Drug Pricing Transparency and Accountability Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Drug Pricing Transparency and Accountability Act (H.R. 198) is a legislative proposal introduced in the 118th Congress aimed at increasing transparency and accountability in drug pricing. The bill was referred to the House Subcommittee on Health but did not advance further and is currently classified as failed or expired. Specific provisions, detailed text, and official summaries of the bill are not publicly available, limiting detailed analysis. The bill falls under the health policy area and appears to focus on addressing issues related to drug pricing mechanisms, potentially involving reporting requirements or regulatory oversight to enhance transparency in pharmaceutical pricing.
H.R. 198 sought to improve transparency and accountability in drug pricing but did not progress beyond initial referral and is now expired, with limited public information on its specific provisions.
- The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health.
- It is categorized under the health policy area, indicating a focus on drug pricing issues.
- The bill failed to advance and is currently expired, with no publicly available full text or official summary.
['Patients and consumers who seek clearer information on drug pricing.', 'Healthcare providers and payers who require transparency for cost management.', 'Regulatory agencies involved in drug pricing oversight.']
['Lack of publicly available full text and summary limits understanding of implementation requirements and enforcement mechanisms.', 'Potential administrative costs and resource needs for agencies to enforce transparency provisions.', 'Unclear scope of authority granted to regulatory bodies and possible impacts on pharmaceutical industry operations.']
The bill was introduced in the 118th Congress and referred to the House Subcommittee on Health but did not proceed further. It is part of ongoing legislative efforts to address drug pricing transparency, a recurring topic in health policy debates. The failure to advance may reflect competing legislative priorities or challenges in consensus building on drug pricing reforms.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, increased drug pricing transparency could influence pharmaceutical market dynamics, potentially affecting drug development and pricing strategies.', 'Enhanced reporting requirements might increase administrative burdens on pharmaceutical companies and regulatory agencies.', 'Greater transparency could impact insurance coverage decisions and patient access to medications.']
The absence of publicly available full text and official summary for H.R. 198 limits transparency and public oversight. This lack of information restricts the ability of stakeholders to fully assess the bill's provisions, potential impacts, and implementation challenges. Future legislative proposals would benefit from comprehensive public documentation to enable informed debate and accountability.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.